Australian PE firm CPE sells cord blood banking business Cell Care to Generate Life Sciences
Australian middle-market PE firm CPE has agreed to sell Cell Care Group, its cord blood banking business, to Generate Life Sciences.
Stay updated with breaking news from Generate Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Australian middle-market PE firm CPE has agreed to sell Cell Care Group, its cord blood banking business, to Generate Life Sciences.
The acquisition provides the companies with shared scientific knowledge and resources leading to a stronger foundation for advancing newborn stem...
The Cell Care international umbilical cord blood and tissue banking group, which incorporates Insception Biosciences Inc. (Insception) in Canada, today announced that it has been acquired by Generate Life Sciences (Generate).* Generate operates Cord Blood Registry (CBR), North America's largest cord blood bank and one of the world's preeminent stem cell R&D organizations. Insception joins CBR to create a unique, international scientific collaboration to further newborn stem cell and regenerative
/PRNewswire/ -- Generate Life Sciences (Generate) today announced that it has acquired the Cell Care international cord blood banking group (Cell Care), which...
Share this article SAN FRANCISCO, May 19, 2021 /PRNewswire/ -- The global mesenchymal stem cells market size is expected to reach USD 6.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.6% from 2021 to 2028. Mesenchymal stem cells (MSCs) are set to gain popularity among healthcare professionals, to develop novel therapeutics, primarily targeted at the treatment of several immune-mediated disorders. MSCs have been acclaimed effective as a regenerative therapy for skeletal tissue repair and have recently gained tracti...